249 related articles for article (PubMed ID: 28168355)
1. Study of early stage non-small-cell lung cancer using Orbitrap-based global serum metabolomics.
Klupczynska A; Dereziński P; Garrett TJ; Rubio VY; Dyszkiewicz W; Kasprzyk M; Kokot ZJ
J Cancer Res Clin Oncol; 2017 Apr; 143(4):649-659. PubMed ID: 28168355
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of serum amino acid profiles' utility in non-small cell lung cancer detection in Polish population.
Klupczynska A; Dereziński P; Dyszkiewicz W; Pawlak K; Kasprzyk M; Kokot ZJ
Lung Cancer; 2016 Oct; 100():71-76. PubMed ID: 27597283
[TBL] [Abstract][Full Text] [Related]
3. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
[TBL] [Abstract][Full Text] [Related]
4. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study.
Maeda J; Higashiyama M; Imaizumi A; Nakayama T; Yamamoto H; Daimon T; Yamakado M; Imamura F; Kodama K
BMC Cancer; 2010 Dec; 10():690. PubMed ID: 21176209
[TBL] [Abstract][Full Text] [Related]
5. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer.
Xiang C; Jin S; Zhang J; Chen M; Xia Y; Shu Y; Guo R
Int J Biol Markers; 2018 Aug; 33(3):314-320. PubMed ID: 29896992
[TBL] [Abstract][Full Text] [Related]
6. Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy.
Shen J; Ye Y; Chang DW; Huang M; Heymach JV; Roth JA; Wu X; Zhao H
Lung Cancer; 2017 Dec; 114():70-78. PubMed ID: 29173770
[TBL] [Abstract][Full Text] [Related]
7. A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients.
Pamungkas AD; Medriano CA; Sim E; Lee S; Park YH
Mol Med Rep; 2017 Jun; 15(6):4155-4161. PubMed ID: 28487968
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary Study on the Biological Markers for I-IIb Stage Non-small Cell Lung Cancer Based on a Serum-peptidomics].
Hou Y; Guo H; Guo Y; Zhang Y; Han H
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):20-25. PubMed ID: 30674389
[TBL] [Abstract][Full Text] [Related]
9. Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.
Wikoff WR; Hanash S; DeFelice B; Miyamoto S; Barnett M; Zhao Y; Goodman G; Feng Z; Gandara D; Fiehn O; Taguchi A
J Clin Oncol; 2015 Nov; 33(33):3880-6. PubMed ID: 26282655
[TBL] [Abstract][Full Text] [Related]
10. Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
Li J; Liu K; Ji Z; Wang Y; Yin T; Long T; Shen Y; Cheng L
Cancer Sci; 2023 Feb; 114(2):680-689. PubMed ID: 36310111
[TBL] [Abstract][Full Text] [Related]
11. Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Zhuang J; Tang X; Du Z; Yang M; Zhou Y
Talanta; 2016 Nov; 160():636-644. PubMed ID: 27591660
[TBL] [Abstract][Full Text] [Related]
12. Development of LC-QTOF-MS method for human lung tissue fingerprinting. A preliminary application to nonsmall cell lung cancer.
Ciborowski M; Kisluk J; Pietrowska K; Samczuk P; Parfieniuk E; Kowalczyk T; Kozlowski M; Kretowski A; Niklinski J
Electrophoresis; 2017 Sep; 38(18):2304-2312. PubMed ID: 28440547
[TBL] [Abstract][Full Text] [Related]
13. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
Li Y; Song X; Zhao X; Zou L; Xu G
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():147-53. PubMed ID: 24856296
[TBL] [Abstract][Full Text] [Related]
14. Determination of 16 serum angiogenic factors in stage I non-small cell lung cancer using a bead-based multiplex immunoassay.
Klupczynska A; Dereziński P; Matysiak J; Dyszkiewicz W; Kasprzyk M; Kokot ZJ
Biomed Pharmacother; 2017 Apr; 88():1031-1037. PubMed ID: 28192876
[TBL] [Abstract][Full Text] [Related]
15. Application of metabolomics by UHPLC-MS/MS in diagnostics and biomarker discovery of non-small cell lung cancer.
Liu Y; Wu J; Zhang K; Yang Q; Yang J; Cao R; Gu F; Liang J; Liu Y; Hu Y; Hong X; Zeng Y; Zheng Z; Liu L
Transl Cancer Res; 2019 Oct; 8(6):2371-2379. PubMed ID: 35116989
[TBL] [Abstract][Full Text] [Related]
16. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
17. Serum Metabolomics Study of Nonsmoking Female Patients with Non-Small Cell Lung Cancer Using Gas Chromatography-Mass Spectrometry.
Mu Y; Zhou Y; Wang Y; Li W; Zhou L; Lu X; Gao P; Gao M; Zhao Y; Wang Q; Wang Y; Xu G
J Proteome Res; 2019 May; 18(5):2175-2184. PubMed ID: 30892048
[TBL] [Abstract][Full Text] [Related]
18. Changes in serum amino acid levels in non-small cell lung cancer: a case-control study in Chinese population.
Liu K; Li J; Long T; Wang Y; Yin T; Long J; Shen Y; Cheng L
PeerJ; 2022; 10():e13272. PubMed ID: 35469201
[TBL] [Abstract][Full Text] [Related]
19. Exosomal lipids for classifying early and late stage non-small cell lung cancer.
Fan TWM; Zhang X; Wang C; Yang Y; Kang WY; Arnold S; Higashi RM; Liu J; Lane AN
Anal Chim Acta; 2018 Dec; 1037():256-264. PubMed ID: 30292300
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
